Assessing Philips (ENXTAM:PHIA) Valuation After Recent Share Price Pullback

Recent performance snapshot

Without a specific headline event driving attention today, Koninklijke Philips (ENXTAM:PHIA) may still interest you if you are tracking healthcare names with mixed short term and longer term return profiles.

The stock shows a 0.9% decline over the past day and a 2.0% decline over the past week, with a larger 8.4% drop over the past month, while the past 3 months reflect a 7.3% gain.

See our latest analysis for Koninklijke Philips.

At a share price of €24.41, the recent 8.4% one-month share price decline contrasts with a 5.6% year-to-date share price gain and a 3.9% one-year total shareholder return. This suggests momentum has cooled following a stronger stretch.

If Philips' recent pullback has you considering where growth in healthcare might come from next, it could be worth scanning our list of 123 healthcare AI stocks as another way to spot potential ideas in this space.

With Philips trading at €24.41 alongside an indicated discount to some valuation estimates, the key question is whether recent weakness leaves the shares undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 29% Undervalued

At €24.41, the most followed narrative for Koninklijke Philips points to a higher fair value, anchoring that view on a detailed earnings and margin trajectory.

Rising demand from hospitals for productivity and AI driven platforms in areas like patient monitoring, imaging and enterprise informatics is supporting Philips' large equipment order book and could feed through to higher revenue and operating earnings as those orders convert to sales.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue lift, margin rebuild and earnings profile this story is banking on by the late 2020s? The blueprint hinges on a specific growth pace, higher profitability and a very particular earnings multiple that together underpin the higher fair value. The full narrative lays out exactly how those moving parts fit together.

Result: Fair Value of €34.38 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also have to weigh tariff headwinds and ongoing regulatory remediation costs. Either of these factors could pressure margins and challenge that higher value narrative.

Find out about the key risks to this Koninklijke Philips narrative.

Another angle on valuation

While the narrative fair value points to undervaluation at €34.38, the P/E ratio of 25.8x tells a different story, as it sits above both the European Medical Equipment industry average of 22.9x and the peer average of 25x. That richer multiple can mean there is less room for error if growth or margins fall short. This raises the question of which signal you consider more informative.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of opportunity and concern around Philips is clear. If this has caught your attention, move quickly and test the story against the numbers for yourself. You can start by weighing up the 3 key rewards and 1 important warning sign that our model has surfaced and decide how they line up with your own view.

Looking for more investment ideas?

If Philips has sharpened your focus on quality, do not stop here. Widen your search with a few targeted stock ideas that could refresh your watchlist.

• Spot potential value candidates early by checking our list of 226 high quality undervalued stocks, which pairs quality fundamentals with pricing that may appeal to disciplined buyers.
• Prioritise resilience by reviewing 299 resilient stocks with low risk scores, which highlights companies our model scores with lower risk profiles for steadier sleep at night.
• Get ahead of the crowd by scanning our screener containing 584 high quality undiscovered gems, where strong financial traits show up before the companies become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com